U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Chou R, McDonagh MS, Nakamoto E, et al. Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Oct. (Comparative Effectiveness Reviews, No. 38.)

Cover of Analgesics for Osteoarthritis

Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review [Internet].

Show details

References

1.
Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis Rheum. 2008;58:26–35. [PMC free article: PMC3266664] [PubMed: 18163497]
2.
Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998;41(8):1343–55. [PubMed: 9704632]
3.
Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: New insights. Part 1: The disease and its risk factors. Ann Intern Med. 2000;133:635–46. [PubMed: 11033593]
4.
Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(3):377–88. [PMC free article: PMC1856004] [PubMed: 17046965]
5.
Chou R, Fanciullo GJ, Fine PG, et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. J Pain. 2009;10(2):113–30.e22. [PMC free article: PMC4043401] [PubMed: 19187889]
6.
Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64:669–81. [PMC free article: PMC1755499] [PubMed: 15471891]
7.
Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–62. [PubMed: 18279766]
8.
Gotzsche PC. Musculoskeletal disorders. Non-steroidal anti-inflammatory drugs. Clin Evid. 2003;(9):1292–300. [PubMed: 12967421]
9.
van Tulder MW, Scholten R, Koes BW, et al. Non-steroidal anti-inflammatory drugs for low-back pain. Cochrane Database Syst Rev. 2005;(3):CD000396. [PubMed: 10796356]
10.
Tarone RE, Blot WJ, McLaughlin JK. Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am J Therapeutics. 2004;11:17–25. [PubMed: 14704592]
11.
Moore R, Phillips C. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ. 1999;2:45–55.
12.
Blower A, Brooks A, Fenn G, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharm Ther. 1997;11(2):283–91. [PubMed: 9146764]
13.
Bandolier. Cox-2 roundup. [Accessed 31 Mar 2011]. http://www​.medicine.ox​.ac.uk/bandolier/band75/b75-2.html.
14.
Graham GG, Graham RI, Day RO. Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). Current Pharmaceutical Design. 2002;8(12):1063–75. [PubMed: 11945151]
15.
Johnson DL, Hisel TM, Phillips BB. Effect of cyclooxygenase-2 inhibitors on blood pressure. Ann Pharmacother. 2003;37:442–6. [PubMed: 12639178]
16.
Stiller C-O, Hjemdahl P. Endothelial COX-2 inhibition: possible relevance for hypertension and cardiovascular risk? J Hypertens. 2003;21:1615–8. [PubMed: 12923388]
17.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520–8. [PubMed: 11087881]
18.
FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351:1709–11. [PubMed: 15470192]
19.
Aw T-J, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165:490–6. [PubMed: 15710786]
20.
Topol EJ. Failing the public health--rofecoxib, Merck, and the FDA. N Engl J Med. 2004;351:1707–9. [PubMed: 15470193]
21.
USFDA. Alert for Healthcare Professionals: Valdecoxib (marketed as Bextra). [Accessed 31 Mar 2011–2005]. http:​//wwwfdagov/Drugs​/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders​/ucm124649htm.
22.
Hersh EV, Moore PA, Ross GL. Over-the-counter analgesics and anti-pyretics: a critical assessment. Clin Ther. 2000;22(5):500–48. [PubMed: 10868553]
23.
Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330(18):1287–94. [PubMed: 8145785]
24.
Scheiman JM, Elta GH. Gastroduodenal mucosal damage with salsalate versus aspirin: Results of experimental models and endoscopic studies in humans. Semin Arthritis Rheum. 1990;20(2):121–7. [PubMed: 2123561]
25.
Crofford LJ. Rational use of analgesic and antiinflammatory drugs. N Engl J Med. 2001;345:1844–6. [PubMed: 11752364]
26.
Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic cartilage in vitro. Osteoarthritis Cartilage. 1998;6:427–34. [PubMed: 10343776]
27.
Adebowale AO, Cox DS, Liang Z, Eddington ND. Analysis of glucosamine and chondroitin sulfate content in marketed products and the caco-2 permeability of chondroitin sulfate raw materials. Journal of the American Nutraceutical Association. 2000;3(1):37–44.
28.
Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases. Drugs. 2000;60(3):555–74. [PubMed: 11030467]
29.
Bandolier. Bandolier extra, Topical analgesics: a review of reviews and a bit of perspective. [Accessed 31 Mar 2011–2005]. http://www​.medicine.ox​.ac.uk/bandolier/Extraforbando​/Topextra3.pdf.
30.
Mason L, Moore RA, Edwards JE, et al. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ. 2004;328(7446):995. [PMC free article: PMC404501] [PubMed: 15033879]
31.
Bandolier. Topical analgesics introduction. [Accessed 31 Mar 2011]. http://www​.medicine.ox​.ac.uk/bandolier/booth​/painpag/topical/Topintro.html.
32.
Rains C, Bryson HM. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging. 1995;7(4):317–28. [PubMed: 8535059]
33.
Chou R, Helfand M, Peterson K, et al. Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative Effectiveness Review No.6. 2006 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-02-0024.) [PubMed: 20704046]
34.
Shekelle P, Newberry S, Maglione M, et al. Assessment of the Need to Update Comparative Effectiveness Reviews Report of an Initial Rapid Program Assessment 2005–2009. 2009. [PubMed: 21204320]
35.
Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet. 2008;371(9608):270–3. [PubMed: 18207021]
36.
Strand V, Kelman A. Outcome measures in osteoarthritis: randomized controlled trials. Curr Rheumatol Rep. 2004;6:20–30. [PubMed: 14713399]
37.
Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis. 2005;64:29–33. [PMC free article: PMC1755212] [PubMed: 15208174]
38.
McConnell S, Kolopack R, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arth Care Res. 2001;45:453–61. [PubMed: 11642645]
39.
Ware JE Jr, Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Medical Care. 1995;33(4 Suppl):AS264–79. [PubMed: 7723455]
40.
Pham T, Van Der Heijde D, Lassere M, et al. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J Rheumatol. 2003;30(7):1648–54. [PubMed: 12858473]
41.
Whitlock EP, Lin JS, Chou R, et al. Using existing systematic reviews in complex systematic reviews. Ann Intern Med. 2008;148(10):776–82. [PubMed: 18490690]
42.
Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009;62(10):1013–20. [PubMed: 19230606]
43.
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84. [PMC free article: PMC1756728] [PubMed: 9764259]
44.
Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 Suppl):21–35. [PubMed: 11306229]
45.
Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program, J Clin Epidemiol. 2010. [Accessed 26 May 2011]. pp. 513–23. www​.effectivehealthcare​.ahrq.gov/index.cfm​/search-for-guides-reviews-and-reports​/?productid=328&pageaction​=displayproduct. [PubMed: 19595577]
46.
Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323–37. [PubMed: 15862718]
47.
Deeks JJ, Dinnes J, D’Amico R, et al. Evaluating non-randomized intervention studies. Health Technol Assess. 2003;7(27):1–192. [PubMed: 14499048]
48.
Gartlehner G, Hansen RA, Nissman D, et al. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol. 2006;59(10):1040–8. [PubMed: 16980143]
49.
Underwood M, Ashby D, Cross P, et al. Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. BMJ (Clinical research ed). 2008;336(7636):138–42. [PMC free article: PMC2206271] [PubMed: 18056743]
50.
Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002;325(7365):619. [PMC free article: PMC126301] [PubMed: 12242171]
51.
Moore RA, Derry S, Makinson GT, et al. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005;7:R644–R55. [PMC free article: PMC1174947] [PubMed: 15899051]
52.
Dahlberg LE, Holme I, Hoye K, et al. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. Scand J Rheumatol. 2009;38(2):133–43. [PubMed: 19165648]
53.
Emery P, Koncz T, Pan S, et al. Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study. Clin Ther. 2008;30(1):70–83. [PubMed: 18343244]
54.
Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247–55. [PubMed: 10979111]
55.
Singh G, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006;119:255–66. [PubMed: 16490472]
56.
Towheed T, Hochberg MC, Shea B, et al. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. Cochrane Database Syst Rev. 2006;(1):CD000517. [PubMed: 10796384]
57.
Watson M, Brookes ST, Faulkner A, et al. Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee. Cochrane Database Syst Rev. 2005;(3):CD000142. [PubMed: 17636601]
58.
Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008;12(11):1–278. iii. [PubMed: 18405470]
59.
Chang D, Young T, Hsu C, et al. Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis. Clin Rheumatol. 2001;20(2):104–13. [PubMed: 11346221]
60.
Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998;37(9):946–51. [PubMed: 9783758]
61.
Furst D, Hall DB, Roszko J, et al. Efficacy, safety and dose response of meloxicam up to 22.5 mg in the treatment of rheumatoid arthritis (RA): results of a phase III double-blind, placebo controlled trial. Zeitschrift fur Rheumatologie. 2001;60(Suppl 1):38.
62.
Goei The HS, Lund B, Distel MR, et al. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 1997;5(4):283–8. [PubMed: 9404473]
63.
Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol. 1998;37(9):937–45. [PubMed: 9783757]
64.
Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol. 1996;35(Suppl 1):39–43. [PubMed: 8630635]
65.
Hosie J, Distel M, Bluhmki E. Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee. A six-month double-blind study. Clin Drug Invest. 1997;13(4):175–84.
66.
Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol. 1996;35(Suppl 1):35–8. [PubMed: 8630634]
67.
Valat JP, Accardo S, Reginster JY, et al. A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm Res. 2001;50(Suppl 1):S30–4. [PubMed: 11339519]
68.
Wojtulewski JA, Schattenkirchner M, Barcelo P, et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol. 1996;35(Suppl 1):22–8. [PubMed: 8630632]
69.
Yocum D, Fleischmann R, Dalgin P, et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. Arch Intern Med. 2000;160(19):2947. [PubMed: 11041902]
70.
Towheed TE, Judd MG, Hochberg MC, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2005;(3):CD004257. [PubMed: 12804508]
71.
Liang TH, Hsu PN. Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee. Curr Med Res Opin. 2003;19(4):336–41. [PubMed: 12841927]
72.
Perpignano G, Bogliolo A, Puccetti L. Double-blind comparison of the efficacy and safety of etodolac SR 600 mg uid and of tenoxicam 20 mg uid in elderly patients with osteoarthritis of the hip and of the knee. Int J Clin Pharmacol Res. 1994;14(5–6):203. [PubMed: 7672877]
73.
Gomes Freitas G. A double-blind comparison of etodolac and piroxicam in the treatment of osteoarthritis. Curr Med Res Opin. 1990;12(4):255–62. [PubMed: 2150187]
74.
Rogind H, Bliddal H, Klokker D, et al. Comparison of etodolac and piroxicam in patients with osteoarthritis of the hip or knee: A prospective, randomised, double-blind, controlled multicentre study. Clin Drug Invest. 1997;13(2):66–75. [PubMed: 18370453]
75.
Chikanza I, Clarke B, Hopkins R, et al. A comparative study of the efficacy and toxicity of etodolac and naproxen in the treatment of osteoarthritis. Br J Clin Pract. 1994;48(2):67–9. [PubMed: 8024992]
76.
Jennings M, Alfieri D. A controlled comparison of etodolac and naproxen in osteoarthritis of the foot. Lower Extremity. 1997;4:43–8.
77.
Lucker P, Pawlowski C, Friedrich I, et al. Double–blind, randomised, multi–centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm. 1994;14(2):29–38. [PubMed: 7744131]
78.
Alballa S, Al-Arfaj H, Al-Sugair S, et al. Randomized, double-blind, short-term trial of nabumetone versus diclofenac in osteoarthritis of the knee. Curr Ther Res Clin Exp. 1992;52(4):581–6.
79.
Schnitzer TJ, Ballard IM, Constantine G, et al. Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee. Clin Ther. 1995;17(4):602–12. [PubMed: 8565024]
80.
Liyanage SP, Tambar PK. Comparative study of salsalate and aspirin in osteoarthrosis of the hip or knee. Curr Med Res Opin. 1978;5(6):450–3. [PubMed: 350497]
81.
Rostom A, Muir K, Dubé C, et al. Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: A Cochrane Collaboration Systematic Review. Clin Gastroenterol Hepatol. 2007;5:818–28.e5. [PubMed: 17556027]
82.
Cheung R, Cheng T-T, Dong Y, et al. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. Int J Rheum Dis. 2010;13(2):151–7. [PubMed: 20536600]
83.
USFDA. Transcript of the arthritis advisory committee. [Accessed 31 Mar 2011–2001]. http://www​.fda.gov/ohrms​/dockets/ac/01/transcripts/3677t1​.rtf.
84.
Witter J. Celebrex Capsules (Celecoxib) NDA 20-998/S-009 Medical Officer Review. 2000. [cited 2011–31 Mar]. Available from: http://www​.fda.gov/ohrms​/dockets/ac/01/briefing​/3677b1_03_med.pdf.
85.
Juni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ. 2002;324:1287–8. [PMC free article: PMC1123260] [PubMed: 12039807]
86.
Juni P, Sterchi R, Dieppe P. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review’s validity. BMJ. 2003;326:334. [PMC free article: PMC1125191] [PubMed: 12574052]
87.
Scheiman JM. Gastrointestinal outcomes: evidence for risk reduction in patients using coxibs. Am J Manag Care. 2002;8(17 Suppl):S518–28. [PubMed: 12458821]
88.
Goldstein JL. Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib. J Rheumatol Suppl. 2000;60:25–8. [PubMed: 11032099]
89.
Fleischmann RM. Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. J Rheumatol Suppl. 1992;36:32–40. [PubMed: 1474533]
90.
Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999;282(20):1929–33. [PubMed: 10580458]
91.
Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004;63(7):759–66. [PMC free article: PMC1755051] [PubMed: 15194568]
92.
Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med. 1999;107(6A):48S–54S. [PubMed: 10628593]
93.
Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med. 2004;117(2):100–6. [PubMed: 15234645]
94.
Rostom A. Systematic review of the gastrointestinal effects of COX-2 inhibitors 2005. Personal communication. Dec 01, 2005. (slide presentation)
95.
Derry S, Loke YK. Risk of gastointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183–7. [PMC free article: PMC27521] [PubMed: 11073508]
96.
Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60. [PMC free article: PMC2715005] [PubMed: 19482214]
97.
Massó González EL, Patrignani P, Tacconelli S, et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62:1592–601. [PubMed: 20178131]
98.
Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12:570–6. [PubMed: 11505178]
99.
Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52:563–71. [PMC free article: PMC2014603] [PubMed: 11736865]
100.
Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312(7046):1563–6. [PMC free article: PMC2351326] [PubMed: 8664664]
101.
Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. An overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093–9. [PubMed: 10904451]
102.
Garcia Rodriguez LA, Laura Barreales T. Risk of Upper Gastrointestinal Complications Among Users of Traditional NSAIDs and COXIBs in the General Population. Gastroenterology. 2007;132(2):498–506. [PubMed: 17258728]
103.
Hippisley-Cox J, Coupland CRL. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;331(7528) [PMC free article: PMC1298853] [PubMed: 16322018]
104.
Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731–8. [PMC free article: PMC1856452] [PubMed: 16687434]
105.
Laporte J-R, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27(6):411–20. [PubMed: 15144234]
106.
Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal hemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 2002;325:624. [PMC free article: PMC126302] [PubMed: 12242172]
107.
Mellemkjær L, Blot WJ, Sørensen HT, et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol. 2002;53(2):173–81. [PMC free article: PMC1874281] [PubMed: 11851641]
108.
Rahme E, Nedjar H. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology. 2007;46(3):435–8. [PubMed: 17255138]
109.
Mann J, Evans T. Gastrointestinal-related complications in a long-term care population taking NSAIDs versus COX-2 inhibitor therapy. Consultant Pharmacist. 2004;19(7):602–12. [PubMed: 16553490]
110.
USFDA. Advisory Committee Briefing Document: Celecoxib and Valdecoxib Cardiovascular Safety. [Accessed 31 Mar 2011–2005]. http://www​.fda.gov/ohrms​/dockets/ac/05/briefing​/2005-4090B1_03​_Pfizer-Celebrex-Bextra.pdf.
111.
Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99:132–40. [PMC free article: PMC1383759] [PubMed: 16508052]
112.
White WB, Faich G, Borer JS, et al. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol. 2003;92(4):411–8. [PubMed: 12914871]
113.
White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007;99(1):91–8. [PubMed: 17196469]
114.
Solomon S, Wittes J, Finn P, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials. Circulation. 2008;117:2104–13. [PMC free article: PMC2965408] [PubMed: 18378608]
115.
Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086. [PMC free article: PMC3019238] [PubMed: 21224324]
116.
Feng G-S, Ma J-L, Wong BCY, et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World J Gastroenterol. 2008;14(28):4535–9. [PMC free article: PMC2731282] [PubMed: 18680235]
117.
White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002;89:425–30. [PubMed: 11835924]
118.
Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–95. [PubMed: 16943401]
119.
Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–80. [PubMed: 15713944]
120.
Solomon SD, Pfeffer MA, McMurray JJV, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114:1028–35. [PubMed: 16943394]
121.
Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ. 2006;332:1302–8. [PMC free article: PMC1473048] [PubMed: 16740558]
122.
ADAPT Research Group. Lyketsos CG, Breitner JCS, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68(21):1800–8. [PubMed: 17460158]
123.
Song F, Altman DG, Glenny AM, et al. Validity of indirect comparisons for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326:472. [PMC free article: PMC150178] [PubMed: 12609941]
124.
National Institutes of Health. Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer’s disease prevention trial. 2004. [Accessed 31 Mar 2011]. http://www​.nih.gov/news​/pr/dec2004/od-20.htm.
125.
Nissen SE. ADAPT: The Wrong Way to Stop a Clinical Trial. PLOS Clin Trial. 2006;1(7):e35. [PMC free article: PMC1851725] [PubMed: 17111045]
126.
Graham DJ. Review of Epidemiologic Studies on Cardiovascular Risk with Selected NSAIDs. 2005. [Accessed 31 Mar 2011]. http://www​.fda.gov/ohrms​/dockets/ac/05/slides​/2005-4090S2_02_FDA-Graham_files​/frame.htm.
127.
Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021–9. [PubMed: 15582059]
128.
McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;269:1633–44. [PubMed: 16968831]
129.
Helin-Salmivaara A, Virtanen A, Vesalainen R, Grönroos J, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J. 2006;27(14):1657. [PubMed: 16731535]
130.
Rahme E, Watson DJ, Kong SX, et al. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2007;16:493–503. [PubMed: 17086567]
131.
Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59(8):1097–104. [PMC free article: PMC2884183] [PubMed: 18668605]
132.
Andersohn F, Suissa S, Garbe E. Use of First- and Second-Generation Cyclooxygenase-2-Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction. Circulation. 2006;113(16):1950–7. [PubMed: 16618816]
133.
Fischer L, Schlienger R, Matter C, et al. Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy. 2005;25:503–10. [PubMed: 15977911]
134.
Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, et al. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation. 2004;109:3000–6. [PubMed: 15197149]
135.
Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygnease 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475–81. [PubMed: 15705456]
136.
Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330(7504):1366. [PMC free article: PMC558288] [PubMed: 15947398]
137.
Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005;165(9):978–84. [PubMed: 15883235]
138.
Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005;142:157–64. [PubMed: 15684203]
139.
Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med. 2005;142(7):481–9. [PubMed: 15809459]
140.
Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003;163:481–6. [PubMed: 12588209]
141.
Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002;162(10):1111–5. [PubMed: 12020180]
142.
Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet. 2002;359(9301):118–23. [PubMed: 11809254]
143.
Schlienger R, al E. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Pharmacol. 2002;54:327–32. [PMC free article: PMC1874430] [PubMed: 12236854]
144.
Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002;162:1099–104. [PubMed: 12020178]
145.
Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109:2068–73. [PubMed: 15096449]
146.
Velentgas P, West W, Cannuscio CC, et al. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiol Drug Saf. 2006;15(9):641–52. [PubMed: 16392153]
147.
Ray WA, Stein C, JR D, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360(9339):1071–3. [PubMed: 12383990]
148.
Cunnington M, Webb D, Qizilbash N, et al. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiol Drug Saf. 2008;17(6):601–8. [PubMed: 18383442]
149.
Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85(2):190–7. [PubMed: 18987620]
150.
USFDA. FDA Public Health Advisory. FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). 2005. [Accessed 31 Mar 2011]. http:​//wwwfdagov/Drugs​/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders​/ucm150314htm.
151.
Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ. 2002;167(10):1131–7. [PMC free article: PMC134294] [PubMed: 12427705]
152.
Singh G, Graham D, Wang H, et al. Concomitant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis. 2006;65:S61.
153.
Ashworth NL, Peloso PM, Muhajarine N, et al. A population based historical cohort study of the mortality associated with nabumetone, Arthrotec, diclofenac, and naproxen. J Rheumatol. 2004;31(5):951–6. [PubMed: 15124256]
154.
Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289–300. [PubMed: 8037411]
155.
Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477–84. [PubMed: 8435027]
156.
Sandhu GK, Heyneman CA. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann Pharmacother. 2004;38(4):700–4. [PubMed: 14982980]
157.
Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events. Meta-analysis of randomized trials. JAMA. 2006;296(13):1619–32. [PubMed: 16968832]
158.
Hudson M, Rahme E, Richard H, et al. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: A class effect? Arthritis Care & Research. 2007;57(3):516–23. [PubMed: 17394181]
159.
Whelton A, Lefkowith JL, West CR, et al. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int. 2006;70(8):1495–502. [PubMed: 16941030]
160.
Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure. Arch Intern Med. 2009;169(2):141–9. [PubMed: 19171810]
161.
Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ. 2005;330:1370. [PMC free article: PMC558290] [PubMed: 15947399]
162.
Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751–6. [PubMed: 15172772]
163.
Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003;14:240–6. [PubMed: 12606892]
164.
Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol. 2005;3(5):489–98. [PubMed: 15880319]
165.
Soni P, Shell B, Cawkwell G, et al. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. Curr Med Res Opin. 2009;25(8):1841–51. [PubMed: 19530981]
166.
Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharm Ther. 2004;20:373–80. [PubMed: 15298630]
167.
Laine L, Goldkind L, Curtis SP, et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol. 2009;104(2):356–62. [PubMed: 19174782]
168.
Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ. 2003;327:18–22. [PMC free article: PMC164233] [PubMed: 12842950]
169.
Walker AM. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1997;40(2):201–8. [PubMed: 9041931]
170.
Niculescu L, Li C, Huang J, et al. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2009;25(3):729–40. [PubMed: 19210159]
171.
Bombardier C, Peloso PM, Goldsmith CH. Salsalate, a nonacetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis. Salsalate-Diclofenac Study Group. J Rheumatol. 1995;22(4):617–24. [PubMed: 7791151]
172.
Deodhar SD, McLeod MM, Dick WC, et al. A short-term comparative trial of salsalate and indomethacin in rheumatoid arthritis. Curr Med Res Opin. 1977;5(2):185–8. [PubMed: 340137]
173.
Kolodny AL. Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis. J Rheumatol. 1988;15(8):1205–11. [PubMed: 3054094]
174.
Montrone F, Caruso I, Cazzola M. Salsalate in the treatment of rheumatoid arthritis: a double-blind clinical and gastroscopic trial versus piroxicam. I. Clinical trial. J Int Med Res. 1989;17(4):316–9. [PubMed: 2676647]
175.
Fries JF. Toward an Understanding of NSAID-Related Adverse Events: The Contribution of Longitudinal Data. Scand J Rheumatol. 1996;25(Suppl 102):3–8. [PubMed: 8628980]
176.
Fries JF, Ramey DR, Singh G, et al. A reevaluation of aspirin therapy in rheumatoid arthritis. Arch Intern Med. 1993;153(21):2465–71. [PubMed: 8215751]
177.
Fries JF, Williams C, Bloch D. The Relative Toxicity of Nonsteroidal Antiinflammatory Drugs. Arthritis Rheum. 1991;34(11) [PubMed: 1953813]
178.
Singh G, Terry R, Ramey D, et al. Comparative GI Toxicity of NSAIDs. American College of Rheumatology. 1997;40(Suppl 9):S115.
179.
Lee C, Straus WL, Balshaw R, et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004;51(5):746–54. [PubMed: 15478167]
180.
Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;(1):CD004257. [PMC free article: PMC8275921] [PubMed: 16437479]
181.
Wegman A, van der Windt D, van Tulder M, Stalman W, et al. Nonsteroidal antiinflammatory drugs or acetaminophen for osteoarthritis of the hip or knee? A systematic review of evidence and guidelines. J Rheumatol. 2004;31(2):344–54. [PubMed: 14760807]
182.
Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis. 2004;63(8):901–7. [PMC free article: PMC1755098] [PubMed: 15020311]
183.
Temple AR, Benson GD, Zinsenheim JR, et al. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6–12 months) safety of acetaminophen in adult patients with osteoarthritis. Clin Ther. 2006;28(2):222–35. [PubMed: 16678643]
184.
Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol. 2004;159(1):23–31. [PubMed: 14693656]
185.
Rahme E, Pettitt D, LeLorier J. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Arthritis Rheum. 2002;46(11):3046–54. [PubMed: 12428249]
186.
Lewis SC, Langman MJS, Laporte J-R, et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320–6. [PMC free article: PMC1874428] [PubMed: 12236853]
187.
Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113:1578–87. [PubMed: 16534006]
188.
McLaughlin JK, Lipworth L, Chow W-H, et al. Analgesic use and chronic renal failure: a critical review of the epidemiologic literature. Kidney International. 1998;54:679–86. [PubMed: 9734593]
189.
Fored CM, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med. 2001;345:1801–8. [PubMed: 11752356]
190.
Curhan GC, Knight EL, Rosner B, et al. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med. 2004;164:1519–24. [PubMed: 15277282]
191.
Kurth T, Glynn RJ, Walker AM, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis. 2003;42(2):234–44. [PubMed: 12900803]
192.
Rexrode KM, Buring JE, Glynn RJ, et al. Analgesic use and renal function in men. JAMA. 2001;286:315–21. [PubMed: 11466097]
193.
Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med. 2002;162:2204–8. [PubMed: 12390063]
194.
Dedier J, Stampfer MJ, Hankinson SE, et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension. 2002;40:604–8. [PubMed: 12411450]
195.
Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension. 2005;46:500–7. [PubMed: 16103274]
196.
Kurth T, Hennekens CH, Sturmer T, et al. Analgesic use and risk of subsequent hypertension in apparently healthy men. Arch Intern Med. 2005;165:1903–9. [PubMed: 16157836]
197.
Bjordal JM, Klovning A, Ljunggren AE, et al. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007;11(2):125–38. [PubMed: 16682240]
198.
Wandel S, Juni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341 [PMC free article: PMC2941572] [PubMed: 20847017]
199.
Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage. 2010;18(Suppl 1):S28–31. [PubMed: 20399895]
200.
Lee YH, Woo J-H, Choi SJ, et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatology Int. 2010;30(3):357–63. [PubMed: 19544061]
201.
Vlad SC, LaValley MP, McAlindon TE, et al. Glucosamine for pain in osteoarthritis: why do trial results differ. Arthritis Rheum. 2007;56(7):2267–77. [PubMed: 17599746]
202.
McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis. A systematic quality assessment and meta-analysis. JAMA. 2000;283:1469–75. [PubMed: 10732937]
203.
Poolsup N, Suthisisang C, Channark P, et al. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother. 2005;39:1080–7. [PubMed: 15855241]
204.
Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med. 2003;163(13):1514–22. [PubMed: 12860572]
205.
Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;(2):CD002946. [PMC free article: PMC8459392] [PubMed: 15846645]
206.
Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007;56(2):555–67. [PubMed: 17265490]
207.
Rozendaal RM, Koes BW, van Osch GJVM, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med. 2008;148(4):268–77. [PubMed: 18283204]
208.
Wilkens P, Scheel IB, Grundnes O, et al. Effect of Glucosamine on Pain-Related Disability in Patients With Chronic Low Back Pain and Degenerative Lumbar Osteoarthritis: A Randomized Controlled Trial. JAMA. 2010;304(1):45–52. [PubMed: 20606148]
209.
Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60(2):524–33. [PubMed: 19180484]
210.
Mazieres B, Hucher M, Zaim M, et al. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2007;66(5):639–45. [PMC free article: PMC1954603] [PubMed: 17204566]
211.
Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005;52(3):779–86. [PubMed: 15751094]
212.
Moller I, Perez M, Monfort J, et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage. 2010;18(Suppl 1):S32–40. [PubMed: 20399899]
213.
Messier SP, Mihalko S, Loeser RF, et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage. 2007;15(11):1256–66. [PubMed: 17561418]
214.
Sawitzke AD, Shi H, Finco MF, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum. 2008;58(10):3183–91. [PMC free article: PMC2836125] [PubMed: 18821708]
215.
Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis. 2010;69(8):1459–64. [PMC free article: PMC3086604] [PubMed: 20525840]
216.
McAlindon TE. Why are clinical trials of glucosamine no longer uniformly positive? Rheum Dis Clin N Am. 2003;29:789–801. [PubMed: 14603583]
217.
Lopes Vaz A. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res Opin. 1982;8(3):145–9. [PubMed: 7128187]
218.
Rovati L. The clinical profile of glucosamine sulfate as a selective symptom modifying drug in osteoarthritis: current data and prospectives. Osteoarthritis Cartilage. 1997;5(Suppl A):72.
219.
Muller-Fassbender H, Bach GL, Haase W, et al. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage. 1994;2(1):61–9. [PubMed: 11548225]
220.
Qiu GX, Gao SN, Giacovelli G, et al. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimittel-Forschung. 1998;48(5):469–74. [PubMed: 9638313]
221.
Clegg D, et al. Glucosamine, chondroitin sulfate and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795–808. [PubMed: 16495392]
222.
Nowlan C, Wetmore S. Short report: ibuprofen versus glucosamine sulfate. Treating osteoarthritis pain. Can Fam Physician. 2003;49(4):1632. [PMC free article: PMC2214169] [PubMed: 14708929]
223.
Thie NM, Prasad NG, Major PW. Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial. J Rheumatol. 2001;28(6):1347–55. [PubMed: 11409130]
224.
Clegg DO, Reda DJ, Harris CL, et al. The efficacy of glucosamine and chondroitin sulfate in patients with painful knee osteoarthritis (OA): the Glucosamine/chondroitin Arthritis Intervention Trial (GAIT). American College of Rheumatology Annual Scientific Meeting. 2005
225.
Leeb BF, Schweitzer H, Montag K, et al. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol. 2000;27:205–11. [PubMed: 10648040]
226.
Emery P, Kong SX, Ehrich EW, et al. Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review. Clin Ther. 2002;24(8):1225–91. [PubMed: 12240779]
227.
Luyten FP, Geusens P, Malaise M, et al. A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. Ann Rheum Dis. 2007;66(1):99–106. [PMC free article: PMC1798410] [PubMed: 16815864]
228.
Levin B. Celecoxib in adnoma prevention--the PreSAP trial. Slide presentation at: meeting of the FDA Advisory Committee on COX-2 inhibitors and NSAIDS; February 16–18, 2005; Gaithersburg, MD. 2005. [Accessed 31 Mar. 2011]. Available at: http://www​.fda.gov/ohrms​/dockets/ac/05/slides​/2005-4090s1_09_FDA-Levin.ppt.
229.
Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95:1218–22. [PubMed: 15877994]
230.
Fries JF, Bruce B. Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol. 2003;30:2226–33. [PubMed: 14528521]
231.
Lisse J, Espinoza L, Zhao SZ, et al. Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib. J Gerontol A Biol Sci Med Sci. 2001;56(3):M167–75. [PubMed: 11253158]
232.
Izhar M, Alausa T, Folker A, et al. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004;43(3):573–7. [PubMed: 14744921]
233.
Chan F, Hung L, Suen B, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347(26):2104–10. [PubMed: 12501222]
234.
Lai KC, Lam SK, Chu KM, et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. Aliment Pharmacol Ther. 2003;18(8):829–36. [PubMed: 14535877]
235.
Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369(9573):1621–6. [PubMed: 17499604]
236.
Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005;118:1271–8. [PubMed: 16271912]
237.
Garcia Rodriguez LA, Varas C, Patrono C. Differential Effects of Aspirin and Non-Aspirin Nonsteroidal Antiinflammatory Drugs in the Primary Prevention of Myocardial Infarction in Postmenopausal Women. Epidemiology. 2000;11(4):382–7. [PubMed: 10874543]
238.
Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113:2906–13. [PubMed: 16785336]
239.
Pavlicevic I, Kuzmanic M, Rumboldt M, et al. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008;15(3):e372–82. [PubMed: 18953082]
240.
Knijff-Dutmer EAJ, Schut GA, van de Laar MAFJ. Concomitant coumarin-NSAID therapy and risk for bleeding. Ann Pharmacother. 2003;37(1):12–6. [PubMed: 12503926]
241.
Schorr RI, Ray WA, Daugherty JR, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153:1665–70. [PubMed: 8333804]
242.
Battistella M, Mamdami MM, Juurlink DN, et al. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165:189–92. [PubMed: 15668365]
243.
Chung L, Chakravarty EF, Kearns P, et al. Bleeding complications in patients on celecoxib and warfarin1. J Clin Pharm Ther. 2005;30(5):471–7. [PubMed: 16164494]
244.
Knijff-Dutmer EAJ, Van der Palen J, Schut G, et al. The influence of cyclo-oxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users. QJM. 2003;96(7):513–20. [PubMed: 12881594]
245.
Larson RJ, Fisher ES. Should aspirin be continued in patients started on warfarin? A systematic review and meta-analysis. J Gen Intern Med. 2004;19:879–86. [PMC free article: PMC1492499] [PubMed: 15242475]
246.
Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143:241–50. [PubMed: 16103468]
247.
Mahe I, Bertrand N, Drouet L, et al. Paracetamol: a haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol. 2004;59(3):371–4. [PMC free article: PMC1884780] [PubMed: 15752384]
248.
Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998;279:657–62. [PubMed: 9496982]
249.
Mahe I, Caulin C, Bergmann J-F. Does paracetamol potentiate the effects of oral anticoagulants. Drug Saf. 2004;27(5):325–33. [PubMed: 15061686]
250.
Rahme E, Bardou M, Dasgupta K, et al. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford). 2007;46(2):265–72. [PubMed: 16844699]
251.
Rahme E, Nedjar H, Bizzi A, et al. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. Aliment Pharmacol Ther. 2007;26(10):1387–98. [PubMed: 17892525]
252.
Juni P, Rutjes WS, Dieppe PA. The authors respond. BMJ. 2003;327:141–2.
253.
Goldstein JL, Hochberg M, Fort JG, et al. Clinical Trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther. 2010;32:401–13. [PubMed: 20497139]
254.
Goldstein JL, Cryer B, Amer F, et al. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol. 2007;5(10):1167–74. [PubMed: 17916545]
255.
Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–102. [PubMed: 15713943]
256.
Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol. 2004;43(6):985–90. [PubMed: 15028354]
257.
Ko D, Wang Y, Berger AK, et al. Nonsteroidal antiinflammatory drugs after acute myocardial infarction. Am Heart J. 2002;143(3):475–81. [PubMed: 11868054]
258.
MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573–4. [PubMed: 12598144]
259.
Patel TN, Goldberg KC. Use of Aspirin and Ibuprofen Compared With Aspirin Alone and the Risk of Myocardial Infarction. Arch Intern Med. 2004;164(8):852–6. [PubMed: 15111370]
260.
Kurth T, Glynn RJ, Walker AM, et al. Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs. Circulation. 2003;108(10):1191–5. [PubMed: 12939216]
261.
Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101(4):701–10. [PubMed: 16494585]
262.
Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ. 2004;329(7472):948. [PMC free article: PMC524106] [PubMed: 15475342]
263.
Rostom A, Dube C, Jolicoeur E, et al. Gastroduodenal ulcers associated with the use of non-steriodal anti-inflammatory drugs: a systematic review of preventative pharmacological interventions. Canadian Coordinating Office for Health Technology Assessment, Technology Overview. 2004;(12)
264.
Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;(4):CD002296. [PubMed: 12519573]
265.
Acevedo E, Castaneda O, Ugaz M, et al. Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. Scand J Rheumatol Suppl. 2001;30(1):19–24. [PubMed: 11252687]
266.
Agrawal N, Roth S, Graham D, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med. 1991;115(3):195–200. [PubMed: 1905501]
267.
Agrawal N, Van Kerckhove HE, Erhardt LJ, et al. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. Dig Dis Sci. 1995;40(5):1125–31. [PubMed: 7729275]
268.
Bocanegra T, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group. J Rheumatol. 1998;25(8):1602–11. [PubMed: 9712107]
269.
Bolten W, Gomes JA, Stead H, et al. The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheumatol. 1992;31(11):753–8. [PubMed: 1450797]
270.
Chan F, Sung J, Ching J, et al. Randomized trial of low dose misoprostol and naproxen vs nambumetone to prevent recurrent upper gastrointestinal hemorrhage in users on non-steroidal anti-inflammatory drugs. Aliment Pharm Ther. 2001;15(1):19–24. [PubMed: 11136274]
271.
Chandrasekaran A, Sambandam P, Lal H, et al. Double blind, placebo controlled trial on the cytoprotective effect of misoprostol in subjects with rheumatoid arthritis, osteoarthritits and seronegative spondarthropathy on NSAIDs. J Assoc Physicians India. 1991;39(12):919–21. [PubMed: 1816217]
272.
Cohen de Lara A, Gompel H. Two comparative studies of Dosmalfate vs Misoprostol in the prevention of NSAID-induced gastric ulcers in rheumatic patients. Drugs Today (Barc). 2000;36(Suppl A):73–8.
273.
Delmas P, Lambert R, Capron MH. Misoprostol for preventing gastric erosions induced by nonsteroidal antiinflammatory drugs in patients with rheumatic diseases. Rev Rhum Engl Ed. 1994;61(2):115–20.
274.
Dieppe P, Bartlett C, Davey P, et al. Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. BMJ. 2004;(329):31–4. [PMC free article: PMC443450] [PubMed: 15231619]
275.
Elliott S, Yeomans ND, Buchanan RRC, et al. Efficacy of 12 months’ misoprostol as prophylaxis against NSAID- induced gastric ulcers. Scand J Rheumatol. 1994;23(4):171–6. [PubMed: 8091141]
276.
Geis GS. Overall safety of Arthrotec. Scand J Rheumatol Suppl. 1992;96:33–6. [PubMed: 1439622]
277.
Geis GS. Efficacy and upper GI safety of diclofenac/misoprostol, piroxicam and naproxen in patients with osteoarthritis. Drugs. 1993;45(Suppl 1):15. discussion -6. [PubMed: 7685683]
278.
Graham D, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet. 1988;2(8623):1277–80. [PubMed: 2904006]
279.
Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002;162(2):169–75. [PubMed: 11802750]
280.
Hannequin JR. Efficacy of Arthrotec in the treatment of rheumatoid arthritis. Scand J Rheumatol Suppl. 1992;96:7–14. [PubMed: 1439627]
281.
Hawkey CJ, Karrasch J, Szczepanski L, et al. Omeprazole compared with misoprostol for ulers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338(11):727–34. [PubMed: 9494149]
282.
Henriksson K, Uribe A, Sandstedt B, et al. Helicobacter pylori infection, ABO blood group and effect of misoprostol on gastroduodenal mucosa in NSAID-treated patients with rheumatoid arthritis. Dig Dis Sci. 1993;38(9):1688–96. [PubMed: 8359082]
283.
Jensen D, Ho S, Hamamah S, et al. A randomized study of omeprazole compared to misoprostol for prevention of recurrent ulcers and ulcer hemorrhage in high risk patients ingesting aspirin or NSAIDs. Gastroenterology. 2000;118(4 Suppl 2 Pt 1):A892.
284.
McKenna F. Diclofenac/misoprostol: the European clinical experience. J Rheumatol Suppl. 1998;51:21–30. [PubMed: 9596551]
285.
Melo Gomes JA, Roth SH, Zeeh J, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis. 1993;52(12):881–5. [PMC free article: PMC1005220] [PubMed: 8311540]
286.
Raskin J, White R, Jackson J, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens. Ann Intern Med. 1995;123(5):344–50. [PubMed: 7625622]
287.
Raskin J, White R, Jaszewski R, et al. Misoprostol and rantidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol. 1996;91(2):223–7. [PubMed: 8607484]
288.
Roth S, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med. 1993;153(22):2565–71. [PubMed: 8239849]
289.
Saggioro A, Alvisi V, Blasi A, et al. Misoprostol prevents NSAID-induced gastrodudenal lesions in patients with osteoarthritis and rheumatoid arthritis. Ital J Gastroenterol. 1991;23(3):119–23. [PubMed: 1742504]
290.
Silverstein F, Graham D, Senior J, et al. Misoprostol reduces gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123(4):241–9. [PubMed: 7611589]
291.
Valentini M, Cannizzaro R, Poletti M, et al. Nonsteroidal antinflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. J Clin Oncol. 1995;13:2637–42. [PubMed: 7595718]
292.
Verdickt W, Moran C, Hantzschel H, et al. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol. 1992;21(2):85–91. [PubMed: 1570496]
293.
Yeomans N, Tulassay Z, Juhasz L, et al. Comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 1998;338(11):719–26. [PubMed: 9494148]
294.
Spiegel BMR, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with coxibs vs NSAID+PPI: a meta-analysis. Am J Med. 2006;119:448.e27–e36. [PubMed: 16651060]
295.
Chan FKL, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. The Lancet. 2010;376(9736):173–9. [PubMed: 20638563]
296.
Rahme E, Barkun AN, Toubouti Y, et al. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib? Arthritis Care & Research. 2007;57(5):748–55. [PubMed: 17530673]
297.
Ray WA, Chung CP, Stein CM, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology. 2007;133(3):790–8. [PubMed: 17854591]
298.
Dickson DJ. A double-blind evaluation of topical piroxicam gel with oral ibuprofen in osteoarthritis of the knee. Curr Ther Res Clin Exp. 1991;49(2):199–207.
299.
Rother M, Lavins BJ, Kneer W, et al. Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial. Ann Rheum Dis. 2007;66(9):1178–83. [PMC free article: PMC1955127] [PubMed: 17363401]
300.
Sandelin J, Harilainen A, Crone H, et al. Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel. Scand J Rheumatol. 1997;26(4):287–92. [PubMed: 9310109]
301.
Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143(3):238–45. [PubMed: 19380203]
302.
Tiso RL, Tong-Ngork S, Fredlund KL. Oral versus topical Ibuprofen for chronic knee pain: a prospective randomized pilot study. Pain physician. 2010;13(5):457–67. [PubMed: 20859315]
303.
Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004;31(10):2002–12. [PubMed: 15468367]
304.
Zacher J, Burger KJ, Farber L, et al. Topical diclofenac versus oral ibuprofen: A double blind, randomized clinical trial to demonstrate efficacy and tolerability in patients with activated osteoarthritis of the finger joints (Heberden and/or Bouchard arthritis). Aktuelle Rheumatologie. 2001;26(1):7–14.
305.
Mason L, Moore RA, Edwards JE, et al. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskeletal Disorders. 2004;5(28) [PMC free article: PMC516039] [PubMed: 15317652]
306.
Lin Y, Zhang W, Jones A, et al. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ. 2004;329(7461):324. [PMC free article: PMC506853] [PubMed: 15286056]
307.
Evans JM, McMahon AD, McGilchrist MM, et al. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ. 1995;311(6996):22–6. [PMC free article: PMC2550082] [PubMed: 7613317]
308.
Evans JM, McGregor E, McMahon AD, et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM. 1995;(88):551–7. [PubMed: 7648241]
309.
Matthews P, Derry S, Moore RA, et al. Topical rubefacients for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;8(3):CD007403. [PMC free article: PMC4171120] [PubMed: 19588430]
310.
Algozzine GJ, Stein GH, Doering PL, et al. Trolamine salicylate cream in osteoarthritis of the knee. JAMA. 1982;247(9):1311–3. [PubMed: 7038182]
311.
Shackel NA, Day RO, Kellett B, et al. Copper-salicylate gel for pain relief in osteoarthritis: a randomised controlled trial. Med J Aust. 1997;167(3):134–6. [PubMed: 9269267]
312.
Kosuwon W, Sirichatiwapee W, Wisanuyotin T, et al. Efficacy of symptomatic control of knee osteoarthritis with 0.0125% of capsaicin versus placebo. J Med Assoc Thai. 2010;93(10):1188–95. [PubMed: 20973322]
313.
Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004;328:991. [PMC free article: PMC404499] [PubMed: 15033881]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (2.5M)

Other titles in these collections

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...